{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:06:14Z","timestamp":1790805974974,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["#1144791"],"award-info":[{"award-number":["#1144791"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.tips.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T16:43:34Z","timestamp":1538325814000},"page":"982-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping"],"prefix":"10.1016","volume":"39","author":[{"given":"Dunhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-893X","authenticated-orcid":false,"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2018.09.001_bib0005","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrg3555","article-title":"Rare-disease genetics in the era of next-generation sequencing: discovery to translation","volume":"14","author":"Boycott","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the Orphan Drug Act?","volume":"14","author":"Herder","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1089\/gtmb.2011.1522","article-title":"International rare disease research consortium commits to aggressive goals","volume":"15","author":"Baxter","year":"2011","journal-title":"Genet. Test. Mol. Biomarkers"},{"key":"10.1016\/j.tips.2018.09.001_bib0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/gim.2015.42","article-title":"Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs, and engagement approaches in health-systems research?","volume":"18","author":"Potter","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0025","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/0929867324666170718101946","article-title":"NGS technologies as a turning point in rare disease research, diagnosis and treatment","volume":"25","author":"Fernandez-Marmiesse","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tips.2018.09.001_bib0030","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.1503\/cmaj.150823","article-title":"Next-generation sequencing for diagnosis of rare diseases in the neonatal intensive care unit","volume":"188","author":"Daoud","year":"2016","journal-title":"CMAJ"},{"key":"10.1016\/j.tips.2018.09.001_bib0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrg3662","article-title":"Coupling mRNA processing with transcription in time and space","volume":"15","author":"Bentley","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0040","doi-asserted-by":"crossref","first-page":"R181","DOI":"10.1016\/j.cub.2014.11.059","article-title":"Spliceosomes","volume":"25","author":"Chen","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0045","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1126\/science.aac8159","article-title":"Structural basis of pre-mRNA splicing","volume":"349","author":"Hang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.tips.2018.09.001_bib0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/hmg\/11.4.451","article-title":"Categorization and characterization of transcript-confirmed constitutively and alternatively spliced introns and exons from human","volume":"11","author":"Clark","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/ng.259","article-title":"Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing","volume":"40","author":"Pan","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0060","doi-asserted-by":"crossref","first-page":"10940","DOI":"10.1038\/srep10940","article-title":"Revealing missing human protein isoforms based on ab initio prediction, RNA-seq and proteomics","volume":"5","author":"Hu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2018.09.001_bib0065","doi-asserted-by":"crossref","first-page":"8776","DOI":"10.1073\/pnas.1432696100","article-title":"Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein","volume":"100","author":"Xie","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2018.09.001_bib0070","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev.biochem.72.121801.161720","article-title":"Mechanisms of alternative pre-messenger RNA splicing","volume":"72","author":"Black","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.tips.2018.09.001_bib0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00412-013-0407-z","article-title":"Regulation of splicing by SR proteins and SR protein-specific kinases","volume":"122","author":"Zhou","year":"2013","journal-title":"Chromosoma"},{"key":"10.1016\/j.tips.2018.09.001_bib0080","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/355730a0","article-title":"Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm","volume":"355","author":"Pi\u00f1ol-Roma","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.tips.2018.09.001_bib0085","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/15476286.2016.1208893","article-title":"RNA structure in splicing: an evolutionary perspective","volume":"13","author":"Lin","year":"2016","journal-title":"RNA Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0090","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.febslet.2005.02.047","article-title":"Are splicing mutations the most frequent cause of hereditary disease?","volume":"579","author":"L\u00f3pez-Bigas","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tips.2018.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1212\/WNL.61.10.1432","article-title":"Splicing mosaic of the myophosphorylase gene due to a silent mutation in McArdle disease","volume":"61","author":"Fernandez-Cadenas","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2018.09.001_bib0100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2018.09.001_bib0105","first-page":"5085","article-title":"Splicing mutants and their second-site suppressors at the dihydrofolate reductase locus in Chinese hamster ovary cells","volume":"13","author":"Carothers","year":"1993","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/mgg3.19","article-title":"Antisense suppression of donor splice site mutations in the dystrophin gene transcript","volume":"1","author":"Fletcher","year":"2013","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0115","series-title":"RNA Metabolism in Neurodegenerative Diseases","first-page":"31","article-title":"Mechanism of Splicing Regulation of Spinal Muscular Atrophy Genes","author":"Singh","year":"2018"},{"key":"10.1016\/j.tips.2018.09.001_bib0120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2018.09.001_bib0130","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa1410345","article-title":"AVI-7288 for Marburg virus in nonhuman primates and humans","volume":"373","author":"Heald","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA approves eteplirsen for Duchenne muscular dystrophy: the next chapter in the eteplirsen saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0145","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2018.09.001_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/ard.1993.3.383","article-title":"Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial","volume":"3","author":"Bayever","year":"1993","journal-title":"Antisense Res. Dev."},{"key":"10.1016\/j.tips.2018.09.001_bib0155","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00080-6","article-title":"The delivery of antisense therapeutics","volume":"44","author":"Akhtar","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tips.2018.09.001_bib0165","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201705328","article-title":"Advances in biomaterials for drug delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.tips.2018.09.001_bib0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/genes8020051","article-title":"Viral vector-mediated antisense therapy for genetic diseases","volume":"8","author":"Imbert","year":"2017","journal-title":"Genes"},{"key":"10.1016\/j.tips.2018.09.001_bib0175","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2015.04.006","article-title":"The emperor\u2019s new dystrophin: finding sense in the noise","volume":"21","author":"Wilton","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","article-title":"Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B","volume":"76","author":"Crooke","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tips.2018.09.001_bib0185","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tips.2018.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-\u03b1 expression","volume":"274","author":"McKay","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2018.09.001_bib0195","doi-asserted-by":"crossref","first-page":"13467","DOI":"10.1039\/C6CC07447B","article-title":"Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and D-altritol nucleic acid-modified 2\u2032-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro","volume":"52","author":"Le","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.tips.2018.09.001_bib0200","doi-asserted-by":"crossref","first-page":"95169","DOI":"10.1039\/C6RA22346J","article-title":"Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping in vitro","volume":"6","author":"Le","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.tips.2018.09.001_bib0205","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and safety profile of tricyclo-DNA antisense oligonucleotides in Duchenne muscular dystrophy mouse model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.tips.2018.09.001_bib0215","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/nar\/24.15.2966","article-title":"Oligo-2\u2032-fluoro-2\u2032-deoxynucleotide N3\u2032\u2192P5\u2032 phosphoramidates: synthesis and properties","volume":"24","author":"Schultz","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2018.09.001_bib0220","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/138920109789069279","article-title":"Cellular uptake of neutral phosphorodiamidate morpholino oligomers","volume":"10","author":"Iversen","year":"2009","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.tips.2018.09.001_bib0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/108729002760070803","article-title":"Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration","volume":"12","author":"McMahon","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"10.1016\/j.tips.2018.09.001_bib0230","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1042\/BST0350826","article-title":"Cell-penetrating peptide\u2013morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo","volume":"35","author":"Moulton","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tips.2018.09.001_bib0235","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular Mechanisms of Antisense Oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0240","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tips.2018.09.001_bib0245","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/mt.2009.49","article-title":"Rational design of antisense oligomers to induce dystrophin exon skipping","volume":"17","author":"Mitrpant","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0250","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","article-title":"Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides","volume":"90","author":"Dominski","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2018.09.001_bib0255","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JND-170272","article-title":"Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history","volume":"5","author":"Kinane","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.tips.2018.09.001_bib0260","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2012.264","article-title":"Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo","volume":"21","author":"Disterer","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0265","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2018.09.001_bib0270","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2018.09.001_bib0275","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/hmg\/ddu537","article-title":"Becker muscular dystrophy severity is linked to the structure of dystrophin","volume":"24","author":"Nicolas","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0280","first-page":"94","article-title":"Large in-frame deletions of the rod-shaped domain of the dystrophin gene resulting in severe phenotype","volume":"5","author":"Nevo","year":"2003","journal-title":"Isr. Med. Assoc. J."},{"key":"10.1016\/j.tips.2018.09.001_bib0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145620","article-title":"Deletion of dystrophin in-frame exon 5 leads to a severe phenotype: guidance for exon skipping strategies","volume":"11","author":"Toh","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2018.09.001_bib0290","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/gb4150","article-title":"Exon identity crisis: disease-causing mutations that disrupt the splicing code","volume":"15","author":"Sterne-Weiler","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0295","first-page":"2675","article-title":"The missing puzzle piece: splicing mutations","volume":"6","author":"Lewandowska","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.tips.2018.09.001_bib0300","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/humu.9477","article-title":"Deletion of exon 16 of the dystrophin gene is not associated with disease","volume":"28","author":"Schwartz","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tips.2018.09.001_bib0305","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tips.2018.09.001_bib0310","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tips.2018.09.001_bib0315","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2018.09.001_bib0320","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for Duchenne muscular dystrophy: the FDA faces a difficult choice","volume":"24","author":"Stein","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0325","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2018.09.001_bib0330","doi-asserted-by":"crossref","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production","volume":"90","author":"Charleston","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2018.09.001_bib0335","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3233\/ISB-00142","article-title":"Distributions of exons and introns in the human genome","volume":"4","author":"Sakharkar","year":"2004","journal-title":"In Silico Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0340","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ceb.2007.07.001","article-title":"Dysferlin and muscle membrane repair","volume":"19","author":"Han","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.tips.2018.09.001_bib0345","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1600-0854.2007.00573.x","article-title":"Dysferlin in membrane trafficking and patch repair","volume":"8","author":"Glover","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.tips.2018.09.001_bib0350","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.4103\/0366-6999.190671","article-title":"Dysferlin gene mutation spectrum in a large cohort of Chinese patients with dysferlinopathy","volume":"129","author":"Jin","year":"2016","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.tips.2018.09.001_bib0355","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1212\/01.wnl.0000204358.89303.81","article-title":"Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy","volume":"66","author":"Sinnreich","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.tips.2018.09.001_bib0360","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/JND-150109","article-title":"Exon 32 skipping of dysferlin rescues membrane repair in patients\u00e9 cells","volume":"2","author":"Barth\u00e9l\u00e9my","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.tips.2018.09.001_bib0365","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jmedgenet-2013-102119","article-title":"Normal and aberrant splicing of LMNA","volume":"51","author":"Luo","year":"2014","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0370","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.yexcr.2007.03.028","article-title":"\u201cLaminopathies\u201d: a wide spectrum of human diseases","volume":"313","author":"Worman","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.tips.2018.09.001_bib0375","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2015.8","article-title":"Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies","volume":"22","author":"Scharner","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0380","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.nephro.2016.09.001","article-title":"Alport syndrome: hereditary nephropathy associated with mutations in genes coding for type IV collagen chains","volume":"12","author":"Heidet","year":"2016","journal-title":"Nephrol. Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome \u2013 insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.tips.2018.09.001_bib0390","doi-asserted-by":"crossref","first-page":"E1652","DOI":"10.1002\/humu.21312","article-title":"The Alport syndrome COL4A5 variant database","volume":"31","author":"Crockett","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tips.2018.09.001_bib0395","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype\u2013phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.tips.2018.09.001_bib0400","doi-asserted-by":"crossref","first-page":"14671","DOI":"10.1038\/ncomms14671","article-title":"Structural basis of homo- and heterotrimerization of collagen I","volume":"8","author":"Sharma","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2018.09.001_bib0405","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1146\/annurev.biochem.77.032207.120833","article-title":"Collagen structure and stability","volume":"78","author":"Shoulders","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.tips.2018.09.001_bib0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/hmg\/ddu444","article-title":"Modeling type II collagenopathy skeletal dysplasia by directed conversion and induced pluripotent stem cells","volume":"24","author":"Okada","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tips.2018.09.001_bib0415","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/CCID.S54681","article-title":"Dystrophic epidermolysis bullosa: a review","volume":"8","author":"Shinkuma","year":"2015","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.tips.2018.09.001_bib0420","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2018.09.001_bib0425","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005054","article-title":"Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy","volume":"4","author":"Kendall","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2018.09.001_bib0430","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/mt.2009.320","article-title":"Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo","volume":"18","author":"Hu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tips.2018.09.001_bib0435","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1038\/ncomms10981","article-title":"Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice","volume":"7","author":"Han","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2018.09.001_bib0440","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.7150\/thno.21529","article-title":"Nucleic acid-based theranostics for tackling Alzheimer\u2019s disease","volume":"7","author":"Chakravarthy","year":"2017","journal-title":"Theranostics"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614718301457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614718301457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:07:23Z","timestamp":1759050443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614718301457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":88,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0165614718301457"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2018.09.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}